Tenax Therapeutics (Tenax Therapeutics) Book Value per Share : $6.35 (As of Mar. 2024)

View and export this data going back to 1997. Start your Free Trial

What is Tenax Therapeutics Book Value per Share?

Tenax Therapeutics's book value per share for the quarter that ended in Mar. 2024 was $6.35.

During the past 12 months, Tenax Therapeutics's average Book Value Per Share Growth Rate was -87.90% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -64.10% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -63.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Tenax Therapeutics was -52.70% per year. The lowest was -64.20% per year. And the median was -61.30% per year.

Tenax Therapeutics's current price is $3.51. Its book value per share for the quarter that ended in Mar. 2024 was $6.35. Hence, today's PB Ratio of Tenax Therapeutics is 0.55.

During the past 13 years, the highest P/B Ratio of Tenax Therapeutics was 17.31. The lowest was 0.01. And the median was 0.16.

Good Sign:

Tenax Therapeutics Inc stock PB Ratio (=0.56) is close to 1-year low of 0.56

Tenax Therapeutics Book Value per Share Historical Data

The historical data trend for Tenax Therapeutics's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tenax Therapeutics Book Value per Share Chart

Tenax Therapeutics Annual Data

Trend

Apr14

Apr15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Book Value per Share

Get a 7-Day Free Trial

895.96

586.31

269.52

52.11

27.15

Tenax Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Book Value per Share	Get a 7-Day Free Trial															52.45	44.33	37.84	27.15	6.35

Competitive Comparison of Tenax Therapeutics's Book Value per Share

For the Biotechnology subindustry, Tenax Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tenax Therapeutics's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tenax Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Tenax Therapeutics's PB Ratio falls into.

Tenax Therapeutics Book Value per Share Calculation

Tenax Therapeutics's Book Value Per Share for the fiscal year that ended in Dec. 2023 is calculated as:

Book Value Per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(8.10	-	0.00)	/	0.30
	=	27.15

Tenax Therapeutics's Book Value Per Share for the quarter that ended in Mar. 2024 is calculated as:

Book Value Per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(12.43	-	0.00)	/	1.96
	=	6.35

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.

Tenax Therapeutics (NAS:TENX) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.

Tenax Therapeutics Book Value per Share Related Terms

Thank you for viewing the detailed overview of Tenax Therapeutics's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Tenax Therapeutics (Tenax Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tenax Therapeutics Inc (NAS:TENX) » Definitions » Book Value per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

101 Glen Lennox Drive, Suite 300, Chapel Hill, NC, USA, 27517

Website

https://www.tenaxthera.com

Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction.

Executives

Robyn Hunter	director	95 SAWYER ROAD, SUITE 110, WALTHAM MA 02453
Eliot M Lurier	officer: Interim CFO	C/O TENAX THERAPEUTICS, INC., ONE COPLEY PARKWAY, SUITE 490, MORRISVILLE NC 27560
Chrisopher Thomas Giordano	director, officer: CEO	C/O TENAX THERAPEUTICS, INC., ONE COPLEY PARKWAY, SUITE 490, MORRISVILLE NC 27560
Armistice Capital, Llc	director	510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital Master Fund Ltd.	director	C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Steven Boyd	director	510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
June Sherie Almenoff	director	C/O BRAINSTORM CELL THERAPEUTICS INC., 1325 AVENUE OF AMERICAS 28TH FLOOR, NEW YORK NY 10019
Michael H. Davidson	director	OMTHERA PHARMACEUTICALS, INC., 707 STATE ROAD, PRINCETON NJ 08540
Declan Doogan	director	C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP, 234 CHURCH STREET, NEW HAVEN CT 06510
Stuart Rich	officer: Chief Medical Officer	C/O TENAX THERAPEUTICS, INC., ONE COPLEY PARKWAY, SUITE 490, MORRISVILLE NC 27560
Illya Keith Maher	director	C/O ARMISTICE CAPITAL, 510 MADISON AVE., 7TH FLOOR, NEW YORK NY 10022
Ronald R Blanck	director	2001 WALNUT HILL LANE, IRVING TX 75038
Gerald T Proehl	director
James P. Mitchum	director	C/O NEPHROGENEX, INC., 79 T.W. ALEXANDER DRIVE, RESEARCH TRIANGLE PARK NC 27709
John P Kelley	officer: Chief Executive Officer	C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502